Clinical trials: Atherosclerotic Cardiovascular Disease, ASCVD
ASCVD, Diabetes
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
The AVOID-DM trial is a multicenter, prospective, randomized study comparing the risk of new-onset diabetes mellitus (DM) between two cholesterol-lowering strategies in patients with prediabetes and established atherosclerotic…
- Conditions
- ASCVD, Diabetes, Statin
- Trial name
- NCT06767774
- Testing
- Combination therapy, High intensity statin monotherapy
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Cardiovascular Diseases
ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent…
- Trial name
- ASA-3C (NCT06676280)
- Testing
- Aspirin, High-intensity statin, Guideline-directed statin therapy
- Where
- 32 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Jung-min Ahn
Atherosclerosis Cardiovascular Disease, Metabolic Syndrome
Comparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health
The goal of this clinical trial is to learn whether following a Mediterranean-style diet or a Carnivore-style diet can improve heart and metabolic health in men and women aged 30-60 years with high LDL cholesterol.
- Conditions
- Atherosclerosis Cardiovascular Disease, Metabolic Syndrome, Dyslipidaemia
- Trial name
- MEDIVORE (NCT07462871)
- Testing
- Carnivore Diet, Mediterranean Diet
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Liverpool John Moores University
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes
- Trial name
- NCT03403556
- Testing
- Rosuvamibe, Monorova
- Where
- 6 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yuhan Corporation
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)
This multi-site study will test whether an opportunistic AI-based CAC screening and notification intervention can improve cholesterol treatment and lower cholesterol levels in adults.
- Trial name
- HEARTWISE (NCT07355894)
- Testing
- AI-Detected CAC Notification and Care Facilitation
- Where
- 6 sites in United States
- Volunteers
- 120,000 people
- Sponsor
- Stanford University
Dyslipidemias, High Cholesterol
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROADWAY (NCT05142722)
- Testing
- Obicetrapib
- Where
- 181 sites in United States, China and 6 more
- Volunteers
- 2,530 people
- Sponsor
- NewAmsterdam Pharma
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
ASCVD, Coronary Artery Calcification
Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)
Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering…
- Trial name
- NOTIFY-ASCVD (NCT05858879)
- Testing
- Notification of patients and clinicians
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- Stanford University
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia…
- Trial name
- NCT06507852
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Novartis
Atherosclerotic Cardiovascular Disease
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
This study looks at how well a new medicine, NNC0385-0434, works to lower blood cholesterol levels. Participants will either get NNC0385-0434 as a tablet (a potential new medicine), or placebo as a tablet (a dummy medicine that…
- Trial name
- NCT04992065
- Testing
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, NNC0385-0434 A 100 mg
- Where
- 44 sites in United States, Belgium and 5 more
- Volunteers
- 267 people
- Sponsor
- Novo Nordisk A/S
ASCVD
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.
- Trial name
- cvMOBIUS (NCT04197453)
- Where
- 164 sites in United States, Canada
- Volunteers
- 752 people
- Sponsor
- Amgen
Hypertension, Hyperlipidemias
Penn Medicine Healthy Heart
To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is…
- Trial name
- NCT06062394
- Testing
- Penn Med Healthy Heart Program
- Where
- United States
- Volunteers
- 1,980 people
- Sponsor
- University of Pennsylvania
Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
- Trial name
- NCT07196280
- Testing
- 5-Alpha Reductase Inhibitors
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Non-communicable Diseases (NCD), Neoplams
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
- Conditions
- Non-communicable Diseases (NCD), Neoplams, Cancer, Lung Cancer (NSCLC)
- Trial name
- H4H (NCT07743021)
- Where
- 33 sites in Hungary
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Center for Molecular Fingerprinting Research Nonprofit LLC
Hyperlipidemia
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
This is a randomized, controlled, collaborative, multicenter, pilot implementation science study evaluating the hypothesis that algorithm- and multi-professional team-supported lipid management reduces low density…
- Trial name
- OPTIMIZE ASCVD (NCT07334834)
- Testing
- Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Colorado Prevention Center
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease
The Learning Registry
The Learning Registry is a retrospective, exempt study. Researchers form the Duke Clinical Research Institute (DCRI) will utilize de-identified data managed by Cerner for population health analytics as part of a ongoing registry…
- Trial name
- NCT03911284
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Duke University
Atherosclerotic Cardiovascular Disease
Pelacarsen Roll-over Extension Program
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
- Trial name
- NCT06875973
- Testing
- Pelacarsen (TQJ230)
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 599 people
- Sponsor
- Novartis Pharmaceuticals